3 additional years of workGenentech, Inc. Tax Reduction Investment Plan is a defined contribution plan with a profit-sharing component and 401k feature. This plan has a BrightScope Rating of 86, placing it in the top 15% of all plans in its peer group. This plan is also in the top 15% of plans for Account Balances, Company Generosity, Salary Deferral, and Total Plan Cost. Genentech, Inc. Tax Reduction Investment Plan currently has over 14,500 active participants and over $1.7B in plan assets.
| Address |
1 Dna Way
South San Francisco, CA 94080 |
| Industry | Manufacturing |
| Administrator | Robert Andreatta |
| Net Plan Assets | $1,660,000,000 |
| Total Participants | 15,000 |
| Avg Account Balance | $120,000 |
| Amgen | 89.0 |
| AstraZeneca Pharmaceuticals LP | 85.9 |
| Schering-Plough | 83.9 |
| Hospira | 79.8 |
| Unilever United States | 77.8 |
| Ecolab | 71.9 |
| 1. | Fidelity Managed Income Portfolio | 16% |
| 2. | Vanguard Institutional Index | 12% |
| 3. | Fidelity Growth Company | 12% |
| Investment Adviser | Mercer |
| Auditor | KPMG, Llp |
| Recordkeeper | Fidelity |
| Corporate Trustee | Fidelity |
BrightScope Rating
Comments